Your browser doesn't support javascript.
loading
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium.
Pulsipher, Michael A; Lehmann, Leslie E; Bertuch, Alison A; Sasa, Ghadir; Olson, Timothy; Nakano, Taizo; Gilio, Alfred; Burroughs, Lauri M; Lipton, Jeffrey M; Huang, James N; Dickerson, Kathryn; Bertaina, Alice; Zhuang, Cindy; Malsch, Maggie; Fleming, Mark; Weller, Edie; Shimamura, Akiko; Williams, David A.
Affiliation
  • Pulsipher MA; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
  • Lehmann LE; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Bertuch AA; Baylor College of Medicine, Center for Cell and Gene Therapy and Texas Children's Hospital, Houston, Texas.
  • Sasa G; Baylor College of Medicine, Center for Cell and Gene Therapy and Texas Children's Hospital, Houston, Texas.
  • Olson T; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Nakano T; Children's Hospital Colorado, Aurora, Colorado.
  • Gilio A; Pediatric Hematology & Oncology, Hackensack, NJ.
  • Burroughs LM; Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington.
  • Lipton JM; Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center of New York, New York.
  • Huang JN; UCSF Benioff Children's Hospital and University of California, San Francisco, California.
  • Dickerson K; UT Southwestern Medical Center, Dallas, Texas.
  • Bertaina A; Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, California.
  • Zhuang C; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
  • Malsch M; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Fleming M; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Weller E; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Shimamura A; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Williams DA; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Pediatr Blood Cancer ; 67(10): e28444, 2020 10.
Article in En | MEDLINE | ID: mdl-32776425
ABSTRACT

BACKGROUND:

Recent data show survival after matched unrelated donor (MUD) bone marrow transplantation (BMT) is similar to matched sibling procedures for young patients with severe aplastic anemia (SAA). Donor delays, risk of transplant-related mortality (TRM), and concern about chronic graft versus host disease raise questions about whether MUD BMT or immune suppression therapy (IST) should be preferred initial therapy for young patients lacking matched sibling donors. PROCEDURE We performed a pilot trial to assess the feasibility of randomizing patients under age 26 with newly diagnosed SAA to receive IST versus MUD BMT. Primary aims assessed the acceptability of randomization and timing of BMT. Secondary aims measured toxicities, response, and survival.

RESULTS:

Sixty-seven patients with possible SAA were screened at nine centers. Of 57 with confirmed SAA, 23 underwent randomization and received therapy with a median follow-up of 18 months. Of 12 randomized to BMT, 10 started BMT as initial therapy at a median of 36 days after randomization. One BMT recipient experienced secondary graft failure, requiring a second procedure. Six of 11 randomized to IST responded, whereas five with refractory disease underwent successful salvage BMT. One patient achieving complete response relapsed after discontinuation of immune suppression and died of infection after salvage BMT.

CONCLUSIONS:

This feasibility study showed that a high percentage of patients underwent randomization and received up-front MUD BMT. Our study lays the groundwork for a larger randomized trial that will define best initial therapy for young patients with SAA who have an available MUD.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Bone Marrow Transplantation / Patient Selection / Time-to-Treatment / Immunosuppressive Agents / Anemia, Aplastic Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Bone Marrow Transplantation / Patient Selection / Time-to-Treatment / Immunosuppressive Agents / Anemia, Aplastic Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Language: En Year: 2020 Type: Article